School of Public Health, Fudan University, Shanghai, China.
Shenzhen Campus of Sun Yat-sen University, Shenzhen, China.
BMJ Open. 2024 Aug 24;14(8):e081129. doi: 10.1136/bmjopen-2023-081129.
Despite the favourable efficacy of antiretroviral therapy (ART), HIV/AIDS continues to impose significant disease burdens worldwide. This study aims to systematically review published prognostic prediction models for survival outcomes of treatment experienced people living with HIV (TE-PLHIV), to describe their characteristics, compare their performance and assess the risk of bias and real-world clinical utility.
Studies will be identified through a comprehensive search in PubMed, EMBASE, Scopus, the Cochrane Library, and OpenGrey databases. Two reviewers will independently conduct a selection of eligible studies, data extraction and critical appraisal. Included studies will be systematically summarised using appropriate tools designed for prognostic prediction modelling studies. Where applicable, evidence will be summarised with meta-analyses.
Ethical approval is not required because only available published data will be analysed. The results of this work will be published in a peer-reviewed journal.
PROSPERO registration number CRD42023412118.
尽管抗逆转录病毒疗法(ART)具有良好的疗效,但艾滋病毒/艾滋病仍在全球造成重大疾病负担。本研究旨在系统地综述已发表的用于预测治疗经验丰富的艾滋病毒感染者(TE-PLHIV)生存结局的预后预测模型,描述其特征,比较其性能,并评估偏倚风险和真实世界的临床实用性。
将通过在 PubMed、EMBASE、Scopus、Cochrane 图书馆和 OpenGrey 数据库中进行全面检索来识别研究。两名评审员将独立进行合格研究的选择、数据提取和关键评估。将使用专门为预后预测模型研究设计的适当工具对纳入的研究进行系统总结。在适用的情况下,将进行荟萃分析以总结证据。
由于仅分析可用的已发表数据,因此不需要伦理批准。本研究的结果将发表在同行评议的期刊上。
PROSPERO 注册号 CRD42023412118。